![](https://ml.globenewswire.com/media/0492fd4c-9844-49ec-ad46-60afd4bdf33a/small/red-jpg.jpg)
RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights
Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019 Preparations ongoing for the potential U.S. …